一例用131I-间碘苄胍和α-甲基对酪氨酸治疗的恶性嗜铬细胞瘤病例。

A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and alpha-methyl-p-tyrosine.

作者信息

Nakagami Y, Nomura K, Kusakabe K, Miko N, Tsushima T, Demura H

机构信息

Department of Medicine, Tokyo Women's Medical College, Japan.

出版信息

Jpn J Med. 1990 May-Jun;29(3):329-33. doi: 10.2169/internalmedicine1962.29.329.

DOI:10.2169/internalmedicine1962.29.329

PMID:1980321

Abstract

A 47-year-old man had surgery for paraaortic paraganglioma in 1980 and 1985. In 1987, his urinary excretion of catecholamines and metabolites was extremely high. Scintigraphy with 131I-metaiodobenzylguanidine (MIBG) showed multiple bone and liver metastases. He was treated twice with infusions of 3.7 GBq of 131I-MIBG. After the first treatment, he had transient hypertension and pain in the back and right leg. Subsequent 131I-MIBG scintigraphy showed that the number of metastatic tumors had decreased. The second treatment was less effective. Excess catecholamines were treated with alpha-methyl-p-tyrosine (MPT), a catecholamine synthesis inhibitor, at doses between 250 and 2000 mg/day, which significantly decreased urinary NE excretion. This is the first case treated with 131I-MIBG in Japan.

摘要

一名47岁男性于1980年和1985年接受了腹主动脉旁副神经节瘤手术。1987年，他的儿茶酚胺及其代谢产物尿排泄量极高。131I-间碘苄胍（MIBG）闪烁显像显示多处骨和肝转移。他接受了两次3.7GBq的131I-MIBG静脉输注治疗。首次治疗后，他出现了短暂性高血压以及背部和右腿疼痛。随后的131I-MIBG闪烁显像显示转移瘤数量减少。第二次治疗效果较差。使用儿茶酚胺合成抑制剂α-甲基对酪氨酸（MPT），剂量为每日250至2000mg，对过量儿茶酚胺进行治疗，显著降低了尿去甲肾上腺素排泄量。这是日本首例用131I-MIBG治疗的病例。